
News|Articles|November 26, 2012
FDA panel votes against making oxybutynin transdermal patch OTC
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































